E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Isolated Systolic Hypertension |
|
E.1.1.1 | Medical condition in easily understood language |
Isolated Systolic Hypertension |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10050591 |
E.1.2 | Term | Isolated systolic hypertension |
E.1.2 | System Organ Class | 100000004866 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluate safety and tolerability of SER100 vs. placebo in patients with ISH |
|
E.2.2 | Secondary objectives of the trial |
Evaluate changes in blood pressure of SER100 vs. placebo in patients with ISH |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Isolated Systolic Hypertension: mean systolic blood pressure ≥ 150 mmHg and mean diastolic blood pressure < 90 mmHg – as determined by daytime continuous ambulatory blood pressure measurement (ABPM)
• Male or female
• Age 55-80 years (both inclusive) at screening
• Patients must be treated with 1-3 antihypertensives on unchanged doses for at least 30 days prior to screening visit. Intake of the underlying 1-3 anti-hypertensives must be witnessed by clinic staff prior to the qualifying ABPM.
• BMI <32 kg/m2
• Written informed consent |
|
E.4 | Principal exclusion criteria |
• Acute myocardial infarction in the last 6 months before screening
• Stroke in the last 6 months before screening
• Uncompensated heart failure (NYHA Class IV)
• Angina pectoris with an anticipated need for administration of short-acting nitrates
• Known, severe sleep apnoea
• Abnormal laboratory values (i.e. > 2 x upper normal limit) at screening for any of
o Creatinine
o ALT
o AST
o ALP
o GGT
o Bilirubin
• Subjects working night shifts (11 PM to 7 AM)
• Participation in any other clinical trial with an investigational medicinal product or device within 1 month prior to randomisation.
• Subjects with upper arm circumference ≤24 cm or ≥ 42 cm.
• Any general condition, serious disease or current evidence of any mental or physical disorder or collaboration attitude (e.g. dementia, substance abuse) which, in the judgment of the investigator makes the subject unsuitable for enrollment, and/or may interfere with the study evaluations or affect subject’s safety and/or may cause risk for poor protocol compliance
• Pregnant or lactating women.
• Female subjects of childbearing potential, or male subjects whose female partner (unless post-menopausal for 1 year or surgically sterile) is unwilling to use adequate contraceptive measures throughout the duration of the study |
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Over the duration of the study |
|
E.5.2 | Secondary end point(s) |
• Mean systolic ambulatory blood pressure
• Mean diastolic ambulatory blood pressure |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Mean day-time ABPM will be calculated based on all readings, but also in separate periods throughout the day (e.g. hours 0-1, 1-3, 3-5, 5-8 after dose 1 and 3; and hours 0-1, 1-3 after dose 2 and 4 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 9 |